Six-Year-Old Girl Regains Vision Through Groundbreaking NHS Gene Therapy for Leber's Congenital Amaurosis
Key Insights
A six-year-old girl with Leber's Congenital Amaurosis (search) has had her vision restored through Luxturna gene therapy, marking the first treatment of its kind on the NHS for this genetic cause of blindness.
New research from Great Ormond Street Hospital (search) and UCL demonstrates that Luxturna can strengthen visual pathways during critical brain development periods in young children with RPE65-related retinal disease (search).
The study of 15 children treated between 2020 and 2023 shows that younger patients experience greater improvement when treated during critical visual development periods.
A six-year-old girl from Hertfordshire has become one of the first patients to have her vision restored through a revolutionary eye gene therapy now available on the NHS, marking a significant milestone in treating inherited blindness. Saffie Sandford, who has the rare genetic condition Leber's Congenital Amaurosis (search) (LCA (search)), underwent treatment with Luxturna at Great Ormond Street Hospital (search), demonstrating the transformative potential of gene therapy for pediatric inherited retinal diseases.
Breakthrough Treatment for Rare Genetic Blindness
Leber's Congenital Amaurosis (search) prevents cells in the eye from producing a specific protein essential for normal vision. Children with this condition experience severely limited vision in daylight and complete blindness in low-light conditions, with the prospect of total vision loss by adulthood. Saffie was diagnosed with LCA (search) at age five after her parents noticed her difficulty seeing in darkness.
Luxturna represents the first gene therapy treatment available for one of the genetic causes of LCA (search). The one-off therapy delivers a healthy copy of the defective gene through direct injection into the eye. Saffie received treatments in April 2025 for her first eye and September for her second eye at Great Ormond Street Hospital (search), following initial diagnosis at Moorfields Eye Hospital.
"We were told that without the treatment, she would be blind by the age of 30," said Saffie's mother, Lisa. "Before she had the treatment, her condition was really life-limiting. She was blind in the dark, which made daily activities challenging."
Dramatic Clinical Improvements
The results of Saffie's treatment have exceeded expectations. Her mother described the transformation: "Having the gene treatment has been life-changing, it's like someone waved a magic wand and restored her sight in the dark. We've been able to take her trick or treating and out to restaurants in the evening – something that was impossible before."
Beyond nighttime vision improvements, Saffie has experienced enhanced peripheral sight during daylight hours, improved hazard detection, better school performance, and the ability to participate in typical childhood activities like playground climbing frames.
Clinical Research Validates Pediatric Gene Therapy
Researchers at Great Ormond Street Hospital (search) and University College London have published new evidence demonstrating Luxturna's effectiveness in strengthening visual pathways during critical brain development periods. The study followed 15 children treated with the gene therapy between 2020 and 2023, focusing on patients with RPE65-related retinal disease (search).
The research included patients ranging from 15 months to 12 years old. Critically, the youngest children showed the most significant improvements, highlighting the importance of early intervention during critical visual development periods. While older children experienced limited changes in visual clarity and accuracy, younger patients benefited substantially from treatment delivered during optimal developmental windows.
Novel Assessment Methods for Pediatric Patients
The research team employed pattern visual evoked potentials (VEPs), a painless diagnostic test measuring signal transmission from the retina to the visual cortex. This objective assessment method proves particularly valuable for very young children or those with neurodevelopmental conditions who cannot complete traditional vision tests.
"For the first time, we've been able to show objectively that gene therapy can strengthen the visual pathways in babies and young children who are living with this rare eye condition," said Rob Henderson, consultant ophthalmologist at Great Ormond Street Hospital (search). "For many of the families we work with, even small improvements in their child's ability to see the world around them make a profound difference."
Future Implications and Long-term Monitoring
While researchers do not characterize Luxturna as a cure, they express optimism about long-term outcomes. The team plans to gather extended follow-up data to assess the therapy's durability and long-term safety profile.
Henderson emphasized the broader implications: "This research highlights not only the potential of gene therapy to change what's possible for children with inherited retinal disease (search), but also the importance of developing age-appropriate outcome measures. Pattern VEPs could help set a new standard for how future paediatric gene therapy trials are assessed around the world."
The successful treatment represents a significant advancement in pediatric ophthalmology and gene therapy, offering hope for families facing inherited retinal diseases while establishing new standards for clinical assessment in young patients.